COMMUNIQUÉS West-GlobeNewswire

Biomea Fusion to Participate at Upcoming Investor Conferences
12/05/2026
SAN CARLOS, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that management will participate in [...]
Jushi Holdings Inc. Reports First Quarter 2026 Financial Results
12/05/2026
Revenue of $66.4 million , Up 4% Year-over-Year, Driven by Strong Wholesale Growth and Benefits from Retail Expansion Gross Profit Margin Expanded 460 bps Year-Over-Year to 45.0% , Reflecting Improved Operational [...]
Stereotaxis Reports 2026 First Quarter Financial Results & Business Updates
12/05/2026
Proprietary robotically-navigated MAGiC catheter received U.S. FDA approval in January and is now being utilized at multiple sites across the United States as well as Europe Synchrony digital operating room system [...]
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
12/05/2026
SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today [...]
Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs
12/05/2026
Data presented at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting SEATTLE, May 12, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible [...]
TELA Bio Reports First Quarter 2026 Financial Results
12/05/2026
MALVERN, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial [...]
Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference
12/05/2026
SAN JOSE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and [...]
Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results
12/05/2026
Robust response in highest dose cohort after 36 weeks following a single treatment of EP-104GI Completion of a $63.2 million public offering to enable clinical trials of EP-104GI in additional indications Well- [...]
Nyxoah Publie ses Résultats Financiers et Opérationnels du Premier Trimestre 2026
12/05/2026
INFORMATIONS RÉGLEMENTÉES Nyxoah Publie ses Résultats Financiers et Opérationnels du Premier Trimestre 2026 Le lancement réussi de Genio aux États-Unis génère une croissance trimestrielle séquentielle de 25 % du chiffre [...]
Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108
12/05/2026
Advancing potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug for treatment of IBD Phase 2 Ulcerative Colitis (UC) trial expected to commence 3Q 2026 Strong balance sheet expected to [...]
Lumexa Imaging Announces First Quarter 2026 Results
12/05/2026
RALEIGH, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (Nasdaq: LMRI), one of the nation’s largest providers of outpatient imaging services, today announced results for the first quarter ended March 31, 2026, [...]
Eton Pharmaceuticals to Participate in Upcoming Investor Conferences
12/05/2026
DEER PARK, Ill., May 12, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare [...]
Crescent Biopharma Announces Grants of Inducement Awards
12/05/2026
WALTHAM, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma , Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies [...]
Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update
12/05/2026
Topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE attacks, expected in 3Q2026 Timeline for submission of NDA of deucrictibant IR for the on-demand treatment of HAE [...]
Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
12/05/2026
Deramiocel BLA under active FDA review; PDUFA target action date of August 22, 2026; labeling discussions expected to commence soon HOPE-3 Phase 3 trial met its primary endpoint (PUL v2.0; upper limb function) and all [...]
Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference
12/05/2026
WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms [...]
Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
12/05/2026
Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) by the end of Q3 2026 Medtronic (NYSE: MDT) and Orchestra BioMed intend to pursue late-breaking clinical trial [...]
Spectral AI Announces 2026 First Quarter Financial Results
12/05/2026
Development Work for DeepView ® Systems Continues with Support of Recently Awarded $31.7 Million of Funding from BARDA Reiterates Annual Revenues Guidance DALLAS, May 12, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. ( [...]
COSCIENS Biopharma Inc. Reports Q1 2026 Results
12/05/2026
TORONTO, ONTARIO, May 12, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“ COSCIENS ” or the “ Company ”) today reported its financial and operating results for the first quarter ended [...]

Pages